TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

OLIX

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

OLIX

ST13

US500000079334635

Class

5, 42

Filing

79334635

Registration

7435162

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

45

Latest update

01/05/2025

Classification

Registered

Trademark type

Word

Nice classes

5, 42

Filing date

12/24/2021

Registration date

07/09/2024

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/09/2024

Last transaction

01/05/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

03

Owner location

KR

Examiner

CLARKE, NANCY

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

OliX Pharmaceuticals, Inc.

Representatives

Joesph A. R. Gerber Knobbe, Martens, Olson & Bear, LLP

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Dietary supplements; nucleic acid sequences for medical purposes; cultures of microorganisms for medical use; biotechnological preparations for medical use, namely, cells, recombinant DNA sequences, synthetic RNA sequences, and oligonucleotides for use in treating and repairing damaged human tissue through tissue nanotransfection (TNT); reagent paper for medical purposes; drugs for medical purposes, namely, cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, metabolic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; synthetic peptides for the treatment of metabolic, ophthalmic, cardiovascular, pulmonary, hepatological, respiratory, neurological diseases and disorders; cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; materials for dental fillings; colostral antibodies for medical purposes, monoclonal antibodies for medical purposes, hybrid antibodies for medical purposes; all the foregoing for human use and excluding goods related to the care and feeding of animals and plants

Class 42

Product research and development in the field of biotech technology; scientific research in the field of biotechnology, medical research in the field of biotechnology; scientific research and scientific investigations for medical purposes in the field of biomedicine; scientific research consultation and providing scientific research information both of the foregoing in the field of biomedicine; bacteriological research; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; pharmaceutical research services; scientific research in the field of genetics; medical research laboratory services; Scientific research and scientific investigations for medical purposes, both of the foregoing in the fields of medicine, health and pharmacology; medical research; All the above-mentioned services excluding services related to the care and feeding of animals and plants

Publications

History of USPTO decisions and trademark events.

45 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/04/2025

FICS

FINAL DISPOSITION NOTICE SENT TO IB

12/13/2024

FIMP

FINAL DISPOSITION PROCESSED

12/13/2024

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/09/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

07/09/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

07/09/2024

GPNX

NOTIFICATION PROCESSED BY IB

04/29/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/23/2024

PUBO

PUBLISHED FOR OPPOSITION

04/23/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/10/2024

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

04/10/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/03/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/12/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/07/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/06/2024

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

02/06/2024

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

01/13/2024

GNS1

NOTIFICATION OF SUBSEQUENT FINAL EMAILED

01/08/2024

GNCF

CONTINUATION OF FINAL REFUSAL E-MAILED

01/08/2024

CNCF

ACTION CONTINUING A FINAL - COMPLETED

01/08/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

12/27/2023

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

12/27/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/22/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/21/2023

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

11/21/2023

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

05/24/2023

GNFR

FINAL REFUSAL E-MAILED

05/24/2023

CNFR

FINAL REFUSAL WRITTEN

05/24/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/03/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/02/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/02/2023

ATRV

ATTORNEY REVIEW COMPLETED

02/01/2023

LIME

LIMITATION FROM THE IB - REQUEST EXAM REVIEW

01/12/2023

RFNT

REFUSAL PROCESSED BY IB

01/04/2023

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

12/12/2022

RFRR

REFUSAL PROCESSED BY MPU

12/12/2022

CREV

CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED

10/28/2022

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

10/01/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/29/2022

CNRT

NON-FINAL ACTION WRITTEN

09/28/2022

DOCK

ASSIGNED TO EXAMINER

09/28/2022

CRCV

CORRECTION TRANSACTION RECEIVED FROM IB

07/23/2022

MAFR

APPLICATION FILING RECEIPT MAILED

03/15/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/10/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

03/03/2022

Continuous trademark protection

Get notified about every new filing that threatens OLIX or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.